Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185164 | 0.85 | LMNA (0.56) | TSHRACE2THRATHRBSRD5A2 | |
| SCHEMBL12583708 | 0.85 | LMNA (0.56) | TSHRACE2THRATHRBSRD5A2 | |
| SCHEMBL12125525 | 0.85 | TSHR (0.59) | TSHRACE2THRATHRBSRD5A2 | |
| SCHEMBL29038778 | 0.85 | GLRA1 (0.42) | TSHRACE2THRATHRBKMT2A | |
| SCHEMBL24987703 | 0.85 | MAPT (0.47) | TSHRACE2THRATHRBKMT2A | |
| Hydrochloric Acid SCHEMBL986198 | 0.84 | LMNA (0.55) | TSHRACE2THRATHRBSRD5A2 | |
| Hydrochloric Acid SCHEMBL986200 | 0.84 | LMNA (0.55) | TSHRACE2THRATHRBSRD5A2 | |
| Hydrochloric Acid SCHEMBL6557925 | 0.84 | LMNA (0.55) | TSHRACE2THRATHRBSRD5A2 | |
| SCHEMBL10105619 | 0.83 | PARP1 (0.44) | ACE2THRATHRBALDH1A1SMN1; SMN2 | |
| SCHEMBL10519043 | 0.83 | PDK1 (0.40) | TSHRACE2THRATHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002504529-A | — | — | 2002-02-12 | — | — | JP | claimed |
| EP-1060160-A2 | DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-12-20 | — | — | EP | claimed |
| WO-1999043636-A2 | DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-02 | — | — | WO | claimed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2022121844-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | MIDWESTERN UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-10961211-B2 | Isotopically-stabilized tetronimide compounds | MIDWESTERN UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200262804-A1 | Isotopically-Stabilized Tetronimide Compounds | MIDWESTERN UNIVERSITY | 2020-08-20 | — | — | US | disclosed |
| US-20150316850-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION COMPRISING CARBONYL-CONTAINING POLYHYDROXY AROMATIC RING NOVOLAC RESIN | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-7888504-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080021052-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-24 | — | — | US | disclosed |
| US-5866610-A | Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical as inhibitors of the cellular NA+/H+ exchange or as a diagnostic, and pharmaceutical containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-02 | — | — | US | disclosed |
| EP-0612723-B1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AG (DE) | 1997-08-27 | — | — | EP | disclosed |
| EP-0612723-A1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | TSHR 2647/4885ACE2 1604/4885THRA 3445/4885 |
| US-10961211-B2 | Isotopically-stabilized tetronimide compounds | ASPH, BACE1, DNPEP | TSHR 846/4885ACE2 21/4885THRA 239/4885 |
| US-20200262804-A1 | Isotopically-Stabilized Tetronimide Compounds | ASPH, BACE1, DNPEP | TSHR 846/4885ACE2 21/4885THRA 239/4885 |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, PIK3C2B, PIK3R1 | TSHR 4109/4885ACE2 3417/4885THRA 3607/4885 |
| US-20210094927-A1 | ISOTOPICALLY-STABILIZED TETRONIMIDE COMPOUNDS | ASPH, BACE1, DNPEP | TSHR 846/4885ACE2 21/4885THRA 239/4885 |
| US-20080021052-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, NR4A3 | TSHR 717/4885ACE2 3843/4885THRA 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.